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Abstract
Pgp (P-glycoprotein, MDR1, ABCB1) is an energy-dependent drug efflux pump that is a member of
the ATP-binding cassette (ABC) family of proteins. Preliminary studies have reported that
nonspecific inhibitors of Pgp affect synthesis and esterification of cholesterol, putatively by blocking
trafficking of cholesterol from the plasma membrane to the endoplasmic reticulum, and that
relative increases in Pgp within a given cell type are associated with increased accumulation of
cholesterol. Several key efflux proteins involved in the cholesterol metabolic pathway are
transcriptionally regulated by the nuclear hormone liver X receptor (LXR). Therefore, to examine
the interplay between P-glycoprotein and the cholesterol metabolic pathway, we utilized a high fat,
normal cholesterol diet to upregulate LXRα without affecting dietary cholesterol. Our research
has demonstrated that mice lacking in P-glycoprotein do not exhibit alterations in hepatic total
cholesterol storage, circulating plasma total cholesterol levels, or total cholesterol concentration
in the bile when compared to control animals on either a normal (25% calories from dietary fat) or
high fat (45% calories from dietary fat) diet. However, p-glycoprotein deficient mice (Mdr1a-/-/1b-/-
) exhibit increased hepatic LXRα protein expression and an elevation in fecal cholesterol
concentration when compared to controls.
Background
Cholesterol homeostasis of an organism involves the
interplay of two main input mechanisms (hepatic and
extra-hepatic synthesis of cholesterol, and the intestinal
absorption of dietary and biliary cholesterol), balanced
with a single elimination pathway via the bile (either
through direct excretion into the bile or by conversion to
bile acids). Other pathways such as steroidogenesis, mye-
lination and anabolic growth play a minor role in the
daily cholesterol balance. Physiologically, an organism
has a large but not unlimited capacity to accommodate
increases in dietary uptake. When dietary cholesterol lev-
els exceed the capacity of efflux mechanisms and override
compensatory decreases in biosynthesis, an imbalance in
cholesterol occurs and excessive accumulation ensues.
Several key efflux proteins involved in the cholesterol
metabolic pathway are transcriptionally regulated by the
nuclear hormone liver X receptor (LXR). When stimulated
by oxysterols, LXR forms an obligate heterodimer with
retinoid X receptor (RXR) and binds to specific DNA
response elements, inducing the expression of genes
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involved in cholesterol efflux pathways [1]. The LXR/RXR
dimer can be activated by ligands for either receptor,
resulting in a complex interplay between dietary fat and
cholesterol induction of the nuclear receptor response [2].
LXRα is highly expressed in the liver, and is also found in
adipose, intestine, kidney and macrophages, while LXRβ
is ubiquitous.
Pgp (P-glycoprotein, MDR1, ABCB1) is an energy-
dependent drug efflux pump that is a member of the ATP-
binding cassette (ABC) family of proteins [3]. Preliminary
studies have reported that nonspecific inhibitors of Pgp
inhibit synthesis and esterification of cholesterol, puta-
tively by blocking trafficking of cholesterol from the
plasma membrane to the endoplasmic reticulum [4,5],
and that relative increases in Pgp within a given cell type
are associated with increased accumulation of cholesterol
[6,7]. These findings provide indirect evidence supporting
a physiologic function for Pgp in the homeostasis of cho-
lesterol. At the whole animal level, a Pgp deficient mouse
model (Mdr1a-/-/1b-/-) exhibited a decrease in hepatic cho-
lesterol accumulation and enhanced esterification when
compared to control mice. However, these animals did
not appear to display any change in dietary cholesterol
absorption [8].
As much of the evidence surrounding the Pgp and choles-
terol interaction is correlative, our analysis was under-
taken to establish a specific interface between Pgp
function and the cholesterol metabolic pathway. Using a
p-glycoprotein knockout mouse model (Mdr1a-/-/1b-/-),
we examined the effect of Pgp deficiency on the plasma
cholesterol, hepatic cholesterol storage and cholesterol
excretion. We then evaluated hepatic LXRα expression
and downstream targets to shed light on the complex
interaction between this membrane-bound protein and
cholesterol metabolic pathways. Using dietary fat as a nat-
ural LXR ligand, we assessed hepatic LXRα expression in
animals fed cholesterol-controlled diets (0.02%) corre-
sponding to normal dietary fat content (NF; 25% calories
from lipids) and high dietary fat content (HF; 45% calo-
ries from lipids).
Methodology
Male P-glycoprotein knockout mice in an FVB back-
ground (FVB.129P2-Abcb1atm1BorAbcb1btm1Bor  N12) and
FVB control mice were obtained from Taconic Farms Inc.
and maintained for 12 weeks on either a normal fat
(NFNC; 25% of calories from fat; n = 8 per genotype) or
high fat diet (HFNC; 45% of calories from fat; n = 8 per
genotype) containing 0.02% cholesterol (Research Diets).
All animal protocols were approved by the University of
British Columbia's Animal Care Committee and conform
to the Canadian Council on Animal Care guidelines.
Total cholesterol
Fecal lipids were extracted using a Folch extraction proto-
col [9]. Briefly, approximately 100 mg of feces was
homogenized for 2 min in a 2:1 CHCl3:CH3OH solution
(20:1 chloroform/methanol to fecal mass).
Homogenates were oscillated overnight at room tempera-
ture and then filtered through glass wool. Filtrate was
washed with 0.9% saline and centrifuged at 1000 g and
4°C for 10 minutes. The upper phase was removed and
the interface washed three times with pure upper phase.
The lower phase was then dried under nitrogen gas. Lipid
films were reconstituted in 300 μl of 10% Triton-X in iso-
propanol. Total fecal cholesterol levels were then deter-
mined using the Wako Cholesterol E assay kit.
PLTP activity
Plasma PLTP activity was determined via the transfer of a
fluorescent substrate from donor to acceptor (PLTP activ-
ity assay kit, Roar Biomedicals). Plasma total cholesterol
levels were determined using an enzymatic colorimetric
assay (Cholesterol E kit, Wako Chemicals).
Western blotting (hepatic LXR expression)
Liver samples weighing 30–50 mg were homogenized in
700 μl of RIPA buffer containing 1 μM PMSF and 1% Pro-
tein Inhibitor Cocktail (Sigma). The samples were centri-
fuged at 14 000 rpm and 4°C for 15 minutes and the
supernatant was obtained. Protein concentration in each
sample was determined using the bicinchoninic acid assay
(BCA) (Pierce).
For LXRα protein expression, 130 μg of protein was run
on a 1.5 mm thick 12.5%T SDS-polyacrylamide gel and
transferred onto a nitrocellulose membrane (Bio-Rad).
The membrane was blocked with 5% skim milk in Tris-
buffered saline containing 0.1% Tween-20 (TBS-T) for 2
hours at room temperature, cut at the 43 kDa mark, and
incubated in primary antibody overnight at 4°C (1:500
anti-LXRα (Abcam) and 1:300 anti-Histone H1 (Santa
Cruz Biotech)). The secondary antibodies were incubated
for 1 hour at 4°C (1:3000 goat anti-rabbit and 1:3000
goat anti-mouse IgG2A  antibody (Santa Cruz Biotech)
respectively).
The membranes were then exposed to ECL western blot-
ting detection reagents (Amersham Biosciences), and
band density was determined. Data are expressed as the
ratio of LXRα to histone protein expression.
Statistical analyses
Statistical analyses were conducted using JMP software V
5.1 for Windows (SAS Institute Inc, Carey, NC, USA). A
one-way ANOVA was used to establish significant differ-
ences between groups, and different group means wereLipids in Health and Disease 2008, 7:21 http://www.lipidworld.com/content/7/1/21
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then separated by a Tukey-Kramer test for Honestly Signif-
icant Difference (HSD); differences were considered sta-
tistically significant when P < 0.05.
Results
Total cholesterol
Mdr1a-/-/1b-/- animals on either a NF or HF diet did not
exhibit any differences in plasma total cholesterol, hepatic
cholesterol storage, or in the concentration of total choles-
terol excreted in the bile when compared to wild type (Fig.
1a, b and Fig. 2a). However, a significant difference in
fecal total cholesterol levels was observed when compar-
ing Mdr1a-/-/1b-/- animals to wild type (Fig. 2b).
Hepatic LXR protein expression
A significant increase in liver LXRα protein expression was
found in the HF WT group compared to the NF WT (Fig.
3). There was no significant difference in liver LXRα pro-
tein expression when comparing diets in Mdr1a-/-/1b-/- ani-
mals; however, there was a general trend for increased
liver LXRα protein expression. A significant increase in
liver LXRα protein expression was found in the Mdr1a-/-/
1b-/- group compared to the WT group in mice fed a NF
diet. There was no significant difference in liver LXRα pro-
tein expression when comparing Mdr1a-/-/1b-/- to WT mice
fed a HF diet. No significant difference was seen in the HF
diet in LXRα expression.
Total cholesterol efflux from bile (2a) and feces (2b) col- lected from control and P-glycoprotein deficient mice  (Mdr1a/-/-/1b-/-) fed normal fat and high fat diets (Mdr1a/-/-/1b- /- genotype is designated "MDR" in all graphs; FVB wild type  mouse is designated "WT") Figure 2
Total cholesterol efflux from bile (2a) and feces (2b) col-
lected from control and P-glycoprotein deficient mice 
(Mdr1a/-/-/1b-/-) fed normal fat and high fat diets (Mdr1a/-/-/1b-
/- genotype is designated "MDR" in all graphs; FVB wild type 
mouse is designated "WT"). No significant differences in total 
cholesterol in the bile were observed (n = 8; p > 0.05). How-
ever, the Mdr1a/-/-/1b-/- genotype was associated with a signif-
icant increase in fecal cholesterol concentration (n = 7; p < 
0.05). Differing letter designations indicate statistically signifi-
cant data.
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Total cholesterol storage in plasma (1a) and liver (1b) col- lected from control and P-glycoprotein deficient mice  (Mdr1a/-/-/1b-/-) fed normal fat and high fat diets (Mdr1a/-/-/1b- /- genotype is designated "MDR" in all graphs; FVB wild type  mouse is designated "WT") Figure 1
Total cholesterol storage in plasma (1a) and liver (1b) col-
lected from control and P-glycoprotein deficient mice 
(Mdr1a/-/-/1b-/-) fed normal fat and high fat diets (Mdr1a/-/-/1b-
/- genotype is designated "MDR" in all graphs; FVB wild type 
mouse is designated "WT"). No significant differences in total 
cholesterol in the liver or plasma were observed (n = 8; p > 
0.05).
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Plasma PLTP activity
There was no significant difference in PLTP activity when
comparing NF and HF diets; however, there was a general
trend for increased PLTP activity in the WT group fed a HF
diet (Fig. 4). A significant increase in PLTP activity was
seen in Mdr1a-/-/1b-/- mice compared to WT mice fed a NF
diet. These findings of increased PLTP activity, contribut-
ing to cholesterol clearance, and elevation of plasma
HDL, are consistent with the increases in liver LXRα pro-
tein expression.
Hepatic ABCG5 protein expression
In the mouse liver, the level of ABCG5 cholesterol efflux
protein did not show a significant upregulation with gen-
otype or diet (Fig. 5).
Discussion
A connection between the integral membrane ABC trans-
porter P-glycoprotein and the cholesterol metabolic path-
way has been proposed [10]. In vitro, nonspecific
inhibitors of Pgp inhibit cholesterol esterification and
trafficking [5-7], while in vivo research suggests hepatic
accumulation and esterification are enhanced in Mdr1a-/-/
1b-/- mice [8]. Our research has demonstrated that mice
lacking in P-glycoprotein do not exhibit alterations in
hepatic total cholesterol storage, circulating plasma total
cholesterol levels, or total cholesterol concentration in the
bile when compared to control animals on either a nor-
mal (25% calories from dietary fat) or high fat (45% cal-
ories from dietary fat) diet. However, Mdr1a-/-/1b-/- mice
exhibit increased hepatic LXRα protein expression and an
elevation in fecal cholesterol concentration when com-
pared to controls.
LXRs are "cholesterol sensors" which, in response to
excess cholesterol, stimulate its transport to the liver and
facilitate biliary excretion. Various saturated and unsatu-
rated fatty acids are also observed to increase LXRα expres-
sion in cultured rat hepatoma cells[11]. In the rat, high-fat
diet and fasting are associated with an up-regulation of
hepatic LXRa expression, likely through the elevation of
the plasma fatty acid levels [12]. To examine the interplay
Hepatic ABCG5 protein expression in P-glycoprotein defi- cient mice (Mdr1a/-/-/1b-/-) fed normal and high fat diets Figure 5
Hepatic ABCG5 protein expression in P-glycoprotein defi-
cient mice (Mdr1a/-/-/1b-/-) fed normal and high fat diets. No 
significant differences in ABCG5 levels were observed with 
change in dietary fat or with genotype (n = 5; p > 0.05).
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Hepatic LXRa protein expression in P-glycoprotein deficient  mice (Mdr1a/-/-/1b-/-) fed normal and high fat diets Figure 3
Hepatic LXRa protein expression in P-glycoprotein deficient 
mice (Mdr1a/-/-/1b-/-) fed normal and high fat diets. A signifi-
cant increase in protein expression with both the Mdr1a/-/-/
1b-/- genotype and with a high fat diet when compared to wild 
type animals on a normal fat diet (n = 7; p < 0.05 as noted by 
asterisk). Placing an Mdr1a/-/-/1b-/-animal on a high fat diet did 
not result in further upregulation of protein expression.
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Plasma phospholipid transfer protein (PLTP) activity in P- glycoprotein deficient mice (Mdr1a/-/-/1b-/-) fed normal and  high fat diets Figure 4
Plasma phospholipid transfer protein (PLTP) activity in P-
glycoprotein deficient mice (Mdr1a/-/-/1b-/-) fed normal and 
high fat diets. A significant increase in PLTP activity was asso-
ciated with the P-glycoprotein deficient genotype (n = 5; p < 
0.05). Differing letter designations indicate statistically signifi-
cant data.
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between P-glycoprotein and the cholesterol metabolic
pathway, we utilized a high fat, normal cholesterol diet to
upregulate LXRα without affecting dietary cholesterol.
Our data indicate that administration of a chronic HF diet
to mice results in a significant upregulation of LXRα pro-
tein expression when compared to the NF diet wild type
mice. In addition, P-glycoprotein deficient mice fed a nor-
mal chow diet exhibit an equivalent statistically signifi-
cant increase in LXRα expression when compared to wild
type mice. When P-glycoprotein deficient mice are placed
on a chronic HF diet, no further upregulation in LXRα
expression is observed (Fig 3).
In human macrophages, adipocytes, and hepatocytes
[13], LXRα expression is controlled by an auto-regulatory
mechanism. The human LXRα gene promoter contains
three functional LXR response elements (LXREs), one of
which is strongly activated by both LXRα and LXRβ[14].
Although the amount of LXRα mRNA in white mouse adi-
pose tissue increases in response to the synthetic LXR ago-
nist T0901317, murine LXRα is not autoregulated in other
cell types, such as macrophages and hepatocytes [15].
Given the available data, we cannot identify the specific
modulator that results in upregulation of hepatic LXRα
protein expression in the Mdr1a-/-/1b-/-  mouse model;
however, the data strongly support the P-glycoprotein/
cholesterol relationship by demonstrating a significant
upregulation of a top-level cholesterol sensing control
mechanism, strengthening the link between P-glycopro-
tein and the cholesterol metabolic pathway.
To confirm if a rise in hepatic LXRα protein expression
translates to increased LXR activity and upregulation of
downstream targets, we evaluated the activity of plasma
phospholipid transfer protein (PLTP), a known direct tar-
get gene of LXRα. In mice, disruption of PLTP function
dramatically reduces plasma HDL cholesterol concentra-
tion [16]. Treatment with LXRα agonists is known to
result in elevated circulating HDL levels, and it has been
suggested that upregulation of PLTP may be responsible
[17]. Our findings demonstrate that the Mdr1a-/-/1b-/-
mouse model exhibits greater plasma PLTP activity when
compared to wild type mice. A trend toward increased
PLTP activity with high fat diet is also observed, with activ-
ity results closely following hepatic LXRα protein expres-
sion data.
As LXR is known to upregulate transcription of proteins
involved in cholesterol efflux pathways, our finding of
increased LXR expression in the Mdr1a-/-/1b-/-  mouse
model when compared to wild type is congruent with the
observed increase in fecal total cholesterol content (Fig
2b). However, this fecal cholesterol loss may be due to
one or all of the following: increased cholesterol efflux
from the liver via the bile (mediated by the heterodimeric
pair of proteins ABCG5 and 8; [18]); an increase in cho-
lesterol efflux from the enterocyte into the intestinal
lumen via ABCA1 [19] or intestinal ABCG5/8 [20]; or a
decrease in cholesterol uptake from the intestinal lumen
by a yet-unknown protein-facilitated mechanism.
To examine the potential role of cholesterol efflux from
the liver as a contributor to the elevated fecal cholesterol,
we quantified hepatic ABCG5 protein expression (Fig. 5)
and found no significant difference in protein expression
with genotype or diet. As ABCG5/8 heterodimer is the
transporter responsible for cholesterol excretion from the
liver into the bile, these data are in agreement with our
findings of no significant differences in liver cholesterol
storage or bile cholesterol concentration. However, we did
not measure the rate of bile formation, therefore cannot
rule out an increased hepatic cholesterol efflux at this time
(although a significant increase in cholesterol efflux via
this pathway is not likely, as the protein expression of
ABCG5 did not increase in either the Mdr1a-/-/1b-/- mouse
model or with a chronic HF diet).
The second possible cause of elevated fecal cholesterol in
the Mdr1a-/-/1b-/- mouse model is an increase in choles-
terol efflux from the enterocyte into the lumen. It has been
demonstrated that activation of the RXR/LXR heterodimer
by either a retinoid or LXR agonist effectively blocks cho-
lesterol absorption [20].
Absorption of cholesterol is a three-step process and
requires uptake across the luminal membrane followed by
cytosolic transport and assembly with lipoproteins, cul-
minating in the subsequent release of cholesterol into
lymphatic or systemic circulation. The interruption of any
one step along this trafficking route with compromise the
absorptive process. Repa et al (2000) attribute the RXR/
LXR heterodimer-induced decrease in cholesterol absorp-
tion to an observed increase in expression of intestinal
ABCA1, a gene product responsible for efflux of cellular
free cholesterol [19]. A subsequent study revealed that
LXR induced upregulation in ABCG5 and G8 protein
expression also contributes to decreased cholesterol
absorption, suggesting that all three proteins play a role in
decreasing cholesterol absorption via increased choles-
terol efflux into the intestinal lumen [20].
A third mechanism that may be responsible for the
observed elevation in fecal cholesterol concentration is
the decreased uptake of dietary and biliary cholesterol. A
number of findings support the presence of a protein-
facilitated cholesterol uptake mechanism located at the
enterocyte brush border. Firstly, cholesterol uptake
appears to be sensitive to protease treatment and is a sat-
urable process [21]. In addition, sterol uptake is highly
selective, with significantly greater uptake of cholesterolLipids in Health and Disease 2008, 7:21 http://www.lipidworld.com/content/7/1/21
Page 6 of 7
(page number not for citation purposes)
occurring across the brush border membrane when com-
pared to similar phytosterols [22,23]. The observed varia-
tion in the cholesterol absorption phenotype in various
mouse strains, and the development of a specific choles-
terol inhibitor, ezetimibe, are strongly suggestive of a
genetic component in the cholesterol absorption process.
However, the identity of a specific protein-facilitated cho-
lesterol uptake mechanism has been highly controversial
[24-28].
Given the indirect relationship between P-glycoprotein
protein expression, activity, and cholesterol uptake, the
direct transport of cholesterol across the plasma mem-
brane by Pgp is unlikely. However, we cannot rule out Pgp
as a contributor to this process. Pgp has been identified as
a functional phospholipid and glycosphingolipid flip-
pase, and is associated with cholesterol microdomains in
cell membranes [29-32]. Based on the identification of
the cholesterol binding site sequence from a benzodi-
azepine receptor protein [33], we have conducted a bioin-
formatics analysis to identify four putative cholesterol
binding sites on the cytosolic portion of the P-glycopro-
tein molecule (Leon et al, in submission). The cytosolic
location of these cholesterol binding sites on the p-glyco-
protein molecule, combined with the evidence support-
ing an indirect relationship between P-glycoprotein and
cholesterol metabolism, suggest that Pgp may act as a cho-
lesterol "dock" which facilitates the transfer of sterol mol-
ecules to cytosolic transport proteins, such as Niemann-
Pick C1-like1 (NPC1L1). The cytosolic cholesterol bind-
ing sites may facilitate the movement of cholesterol from
the exofacial to cytofacial leaflet, assisting in the mainte-
nance of membrane cholesterol asymmetry and supple-
menting the luminal/exofacial leaflet cholesterol gradient,
thus facilitating cholesterol diffusion across the mem-
brane. As P-glycoprotein acts as an efflux transporter and
is found in the luminal surface of epithelial cells, it has the
potential to assist in both cholesterol uptake across the
enterocyte, as well as facilitate cholesterol efflux in the
liver [29].
Conclusion
The establishment of a direct link between P-glycoprotein
and cholesterol metabolic pathway remains elusive. How-
ever, the data presented here further substantiate the con-
nection between this membrane-bound protein and
cholesterol transport. We have observed a significant
increase in cholesterol efflux in P-glycoprotein deficient
animals and established that the lack of P-glycoprotein
results in alterations in the top level of the cholesterol
metabolic pathway via increased expression of LXRα, a
nuclear hormone crucial in orchestrating the complex
processes involved in the trafficking of cholesterol. We
have further postulated a potential mechanism by which
P-glycoprotein may facilitate cholesterol transport across
the membrane and, depending on the location of expres-
sion, supplement both uptake and efflux of sterol mole-
cules.
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